Stephen D. Gillies

Provenance Biopharmaceuticals Corp. engages in the research and development of immune therapeutics for the treatment of cancer. It offers immunocytokine technology, a drug that targets antibodies with immune-stimulating features of cytokines. The company was founded by Stephen D. Gillies and Jason M. Walsh in 2008 and is headquartered in Carlisle, MA.

Delos Advisors Ltd (Delos Capital) is a private equity and venture capital firm founded by Lin Zheng Chen in 2014. The firm is headquartered in Hong Kong.

Galenea Corp. is an emerging biotechnology company which engaged in the discovery of novel therapies for central nervous system (CNC) and respiratory diseases. The firm is focusing initially on utilizing proprietary technologies to generate calcineurin-related treatments for schizophrenia. It also offers synaptic transmission drug discovery platform for alzheimer’s disease (AD), parkinson’s disease, huntington’s disease, epilepsy, bipolar depression, schizophrenia, autism spectrum disorders, and traumatic brain injury. The company was founded Jianzhu chen, Susumu Tonegawa, Maria Karayiorgou, and David J. Gerber in 2004 and is headquartered in Wakefield, MA.

Lexigen Pharmaceuticals Corp. focuses on commercial physical and biological research. The company was founded by Stephen D. Gillies and is headquartered in Billerica, MA.

Potentia Pharmaceuticals, Inc. operates as a biotechnology company. It focuses on the development of novel therapeutics and drug delivery technologies to address chronic inflammatory diseases. The company was founded by Cedric Francois, David Darst, Alec Machiels and Pascal Deschatelets in 2001 and is headquartered in Crestwood, KY.